Panacea Index Logo

Command Palette

Search for a command to run...

A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being.

Journal of substance abuse treatment
August 1, 2021
Nina A Cooperman et al. (4 authors)
Journal ArticleRandomized Controlled TrialResearch Support, N.I.H., ExtramuralHuman StudyClinical
Study Details

Study Goal

The researchers aimed to evaluate the effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) as an adjunct treatment to methadone maintenance therapy (MMT) for reducing illicit opioid use and chronic pain.

Results Summary

Participants receiving MORE showed significantly fewer days of illicit drug use, lower craving, reduced pain, and improved well-being compared to those receiving only MMT. The benefits persisted through the 16-week follow-up.

Population

Individuals in methadone maintenance treatment (MMT) for opioid use disorder with chronic pain.

Effective Dosage

Eight weekly two-hour MORE group sessions.

Duration

8 weeks of intervention, with follow-up at 16 weeks.

Interactions

None mentioned

Extracted Claims (9)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
decrease
baseline adjusted days of illicit drug use
Randomized individuals in MMT
-
evidenced significantly fewer
#1
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
decrease
craving
Randomized individuals in MMT
-
significantly lower levels of
#2
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
decrease
pain
Randomized individuals in MMT
-
significantly lower levels of
#3
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
decrease
physical and emotional limitations
Randomized individuals in MMT
-
significantly lower levels of
#4
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
decrease
depression
Randomized individuals in MMT
-
significantly lower levels of
#5
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
decrease
anxiety
Randomized individuals in MMT
-
significantly lower levels of
#6
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
increase
well-being
Randomized individuals in MMT
-
significantly higher levels of
#7
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
increase
vitality
Randomized individuals in MMT
-
significantly higher levels of
#8
Mindfulness-Oriented Recovery Enhancement (MORE) plus methadone TAU
increase
social functioning
Randomized individuals in MMT
-
significantly higher levels of
#9
Abstract

BACKGROUND: Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse. Mindfulness-Oriented Recovery Enhancement (MORE) is one of the few interventions developed and tested as an integrated treatment to simultaneously address both pain and illicit opioid use; however, this study is the first to evaluate MORE as an adjunct to MMT. METHODS: Randomized individuals in MMT (N = 30) received MORE plus methadone TAU (n = 15) or methadone TAU, only (n = 15). Participants in the MORE arm received their MMT, as usual, and attended eight, weekly, two-hour MORE groups at their MMT clinics. Participants in the TAU arm received their MMT, as usual, and group or individual counseling, as required by the clinic. TAU counseling consisted of relapse prevention, cognitive-behavioral therapy, and supportive treatment. TAU participants did not receive any mindfulness-based intervention. Participants completed assessments at baseline, post-treatment (i.e., 8-weeks post-baseline), and follow-up (i.e., 16-weeks post-baseline). RESULTS: Participants in MORE evidenced significantly fewer baseline adjusted days of illicit drug use and significantly lower levels of craving through 16-week follow-up compared to TAU. Also, Participants in MORE reported significantly lower levels of pain, physical and emotional limitations, depression, and anxiety through 16-week follow-up compared to TAU. Conversely, participants in MORE reported significantly higher levels of well-being, vitality, and social functioning through 16-week follow-up compared to TAU. CONCLUSION: MORE could be an effective adjunct to MMT, and larger trials are warranted.

Medical Subject Headings (MeSH)
Analgesics, OpioidChronic PainHumansIllicit DrugsMethadoneMindfulnessOpiate Substitution TreatmentOpioid-Related DisordersPilot Projects
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality75/10
Citation Metrics
Total Citations35
Citations/Year8.8
Relative Citation Ratio4.26
NIH Percentile91.1%
Research Impact Scores
APT Score0.75
Weight Score2.60
Normalized Score0.69
Related Supplements
A pilot randomized clinical trial of mindfulness-oriented re... | Panacea Index